Document is current

Article History

Received: 30 November 2020

Accepted: 14 February 2021

First Online: 9 April 2021

Compliance with ethical standard

:

: TI has nothing to disclose. AS has nothing to disclose. TK reports grants from, Daiichi-Sankyo and Ono; and personal AstraZeneca, MDS and Taiho. HS has nothing to disclose. HH has nothing to disclose. YO has nothing to disclose. KY has nothing to disclose. SM reports grants and personal fees from Ono; and grants from Sumitomo Dainippon Pharma, Astellas, AJINOMOTO, Toray and PFDeNA. TY reports grants and personal fees from Taiho and Chugai; and grants from Ono, Amgen, Parexel International, MSD, DS, SD, and S; and personal fees from Takeda, Lilly, Bayer, and Merck Biopharma. TK reports personal fees from Taiho, Lilly, Ono, Kaken, Johnson & Johnson, Medtronic, Olympus, Intuitive Surgical and Verb Surgical. AO has nothing to disclose. KS reports grants and personal fees from Astellas Pharma, Lilly, Ono, Taiho and Merck; and grants from Dainippon Sumitomo, Daiichi Sankyo, Chugai, and Medi Science; and personal fees from Bristol-Myers Squibb, Takeda Pharmaceuticals, Pfizer Inc, Novartis, AbbVie Inc, Yakult, and GlaxoSmithKline. GI reports grants and personal fees from Daiichi Sankyo; and grants from Ono; and personal fees from Lilly, Novartis, Chugai, and Oncolys BioPharma.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions

: Informed consent to be included in the study, or the equivalent, was obtained from all patients.

Free to read: This content has been made available to all.